

Ro 09-1679, A NOVEL THROMBIN
INHIBITOR

TSUTOMU KAMIYAMA, TAKAYUKI UMINO,
NOBORU NAKAYAMA, YOSHIKO ITEZONO,
TOMOKO SATOH, YUKO YAMASHITA,
AKIKO YAMAGUCHI and KAZUTERU YOKOSE


Nippon Roche Research Center,
200 Kajiwara, Kamakura, Kanagawa 247, Japan

(Received for publication September 2, 1991)

Among the serine proteases involved in thrombosis and hemostasis, thrombin plays a key role in blood coagulation; for example, it converts fibrinogen into fibrin and activates the cofactor V and VIII by a specific cleavage of certain peptide bonds next to arginine in physiological substrates. It also acts as a potent agonist for platelet aggregation. Therefore, thrombin is an effective target for an anticoagulant agent. During our screening program for thrombin inhibitors, we isolated a novel inhibitor, Ro 09-1679 (**1**), from the culture broth of strain NR6773 collected at Minamishitara, Aichi Prefecture, Japan. The strain was identified as *Mortierella alpina* Peyronel^{1,2)} on the basis of its morphological properties. In this paper, the fermentation, isolation, structural elucidation and biological properties of **1** are reported.

The stock culture of the producing organism, *M. alpina* NR6773, (stored at -80°C) was thawed and

Fig. 1. Isolation procedure of Ro 09-1679.



200 μl was inoculated into five, 500-ml Erlenmeyer flasks each containing 100 ml of seed medium consisting of glycerol 3%, glucose 2%, Polypepton 0.5%, yeast extract 0.2%, NaCl 0.3% and CaCO_3 1%. All were agitated on a rotary shaker for 3 days at 27°C and 190 rpm. Then, the cultures were combined and transferred to a 50-liter jar fermenter containing

Table 1. Physico-chemical properties of Ro 09-1679.

Appearance	Colorless powder
HRFAB-MS (<i>m/z</i>)	Calcd: 526.3103
(M+H) ⁺	Found: 526.3121
Molecular formula	$\text{C}_{22}\text{H}_{39}\text{N}_9\text{O}_6$
UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$	End absorption
$[\alpha]_{\text{D}}^{24}$	-38.7° (<i>c</i> 1.06, H_2O)
IR (KBr) cm^{-1}	3400~3200, 1660, 1560, 1395
Color reaction:	
Positive	Lydon-Smith, I_2 vapor, Sakaguchi, triphenyl, tetrazolium chloride
Negative	FeCl_3 , ninhydrin
Amino acid composition	L-Leu (1), L-Arg (1)

Table 2. NMR chemical shifts of **2** in D_2O .

	^{13}C	^1H
Fumaric acid		
1	176.1	
2 ^c	133.0	6.69 (d, <i>J</i> = 15.6) ^a
3 ^c	140.4	6.73 (d, <i>J</i> = 15.6)
4	170.5	
Arginine 1		
1'	176.3	
2'	56.5	4.40 (dd, <i>J</i> = 7.8, 6.3)
3'	31.0	1.89, 1.78 ^b
4'	27.2	1.65 ^b
5'	43.4	3.20 (t, <i>J</i> = 7.1)
6'	159.6	
Leucine		
1''	176.5	
2''	55.5	4.35 (dd, <i>J</i> = 10.0, 4.5)
3''	42.3	1.69, 1.63 ^b
4''	27.2	1.64 ^b
5''	25.1	0.92 (d, <i>J</i> = 5.9)
6''	23.5	0.87 (d, <i>J</i> = 5.9)
Arginine 2		
1'''	180.9	
2'''	57.4	4.16 (dd, <i>J</i> = 7.8, 4.9)
3'''	31.7	1.85, 1.70 ^b
4'''	27.2	1.57 ^b
5'''	43.5	3.18 (t, <i>J</i> = 7.1)
6'''	159.6	

^a Multiplicity and coupling constant (Hz) are in parentheses.

^b *J* value could not be determined.

^c These assignments are referred to ^{13}C NMR chemical shift values of synthetic fumaric acid⁸⁾.

30 liters of production medium which was the same as the seed medium above. The fermentation was carried out at 27°C for 3 days with agitation at 300 rpm. The thrombin inhibitory activity of **1** was measured by using the Boc-Val-Pro-Arg-methylcoumarylamide (MCA) as a substrate, and the product was measured at the excitation wavelength of 380 nm and emission wavelength of 460 nm³⁾.

The purification procedure is shown in Fig. 1. We isolated 70 mg of **1** as an amorphous powder from 85 liters of culture broth. The physico-chemical properties of **1** are summarized in Table 1. The molecular formula of **1** was determined to be C₂₂H₃₉N₉O₆ on the basis of HRFAB-MS. The ¹H

and ¹³C NMR spectra of **1** in D₂O indicated that **1** existed as an equilibrium mixture similar to that of leupeptin^{4,5)} and suggested the presence of an aldehyde group at the C-terminal since both spectra were complex. This assumption was supported by 1) the reducing properties of **1** which gave a positive reaction to the triphenyl tetrazolium chloride reagent (Table 1), and 2) the presence of weak signal at δ 9.48, assignable to an aldehyde proton in ¹H NMR spectrum of **1**.

In order to exclude a state of equilibrium, **1** was treated with PtO₂-O₂ at pH 7.5 to give oxidation products, **2** and **3**. Since **2** and **3** showed quite similar ¹H and ¹³C NMR spectra and almost identical

Fig. 2. Structure and HMBC correlation of **2**.




Fig. 3. Structure and mass fragmentation pattern of Ro 09-1679 (**1**).




Table 3. Enzyme inhibitory activity of Ro 09-1679.

	Enzyme inhibition (IC ₅₀ μM)			
	Thrombin	Factor Xa	Trypsin	Papain
Ro 09-1679	33.6	3.3	0.04	0.0346
Antipain	12.5	5.1	0.055	0.0458
Leupeptin	15.5	7.9	0.045	0.0124

IC₅₀: The mixture of 195 μl of enzyme solution (final concentration; 0.08 u/ml thrombin, 0.015 u/ml factor Xa, 0.03 u/ml trypsin, 0.076 u/ml papain) and 50 μl inhibitor solution was incubated at 37°C. After 1 minute, 5 μl substrate solution in 100% DMSO (final concentration; 20 μM Boc-Val-Pro-Arg-MCA for thrombin, 120 μM Boc-Ile-Glu-Gly-Arg-MCA for factor Xa, 120 μM Bz-Arg-MCA for trypsin and papain) was added. Fluorescence of 7-amino-4-methylcoumarin (AMC) produced was monitored in 30 seconds intervals up to 180 seconds using spectrophotometric centrifugal analyzer (Cobas Bio, Roche Diagnostica Inc.) at 380 nm excitation and 460 nm emission wavelength.

HRFAB-MS spectra (**2**: m/z 542.3090 (M+H)⁺, **3**: m/z 542.3002 (M+H)⁺; calcd for C₂₂H₄₀N₉O₇: 542.3051), it was suggested that the PtO₂ oxidation of **1** afforded two epimers. The amino acid analysis of **2** indicated that **2** possessed 2 mol of arginine and 1 mol of leucine, while **1**, 1 mol of arginine and 1 mol of leucine (Table 1). This result indicated that the C-terminal end of **1** was arginal.

The ¹H and ¹³C NMR data of **2** are summarized in Table 2. The ¹H signals of amino acid residues were mainly assigned by ¹H-¹H correlation spectroscopy (COSY) and selective coherence transfer experiments^{6,7}. The presence of a fumaric acid residue in **2** was clarified by the ¹H NMR, ¹³C NMR and heteronuclear multiple-bond connectivity (HMBC) experiments of **2**. The coupling constant ($J=15.6$ Hz) between two olefinic protons (2-H and 3-H) indicated an *E*-geometrical configuration. In the HMBC spectrum of **2**, two olefinic protons (2-H and 3-H) showed long-range CH couplings with carbonyl carbons, C-1 (δ 176.1) and C-4 (δ 170.5) (Fig. 2). These results indicated the presence of a fumaric acid residue in **2**. The sequence of each unit in **2** was assigned by the HMBC experiment of **2** (Fig. 2). All of the α -methine protons of the amino acid residues showed long-range CH coupling with the carbonyl carbon of the adjacent unit. Therefore, the structure of **2** was determined to be fumaryl-arginyl-

leucyl-arginine.

From the structure of **2**, we deduced that the structure of Ro 09-1679 is **1**. The structure of **1** was confirmed by FAB-MS fragment analysis (Fig. 3). The configurations of amino acids derived from **1** were determined by HPLC analyses[†] and were found to be all L-configurations. Therefore, the structure of Ro 09-1679 was determined to be fumaryl-L-arginyl-L-leucyl-arginal.

The inhibitory activity of Ro 09-1679 against thrombin, factor Xa, trypsin and papain is shown in Table 3. Ro 09-1679 inhibited the enzyme activities, with IC₅₀ values ranging from 0.03 μM to 34 μM. Ro 09-1679 had no antimicrobial activity.

Acknowledgment

The authors thank Mr. K. NOJIMA of Jeol Ltd. for measurements of high resolution FAB-MS and Drs. M. ARISAWA and T. OKUDA of Nippon Roche Research Center for their valuable advice.

References

- 1) DOMSH, K. H.; W. GAMS & T.-H. ANDERSON: *Mortierella*. In Compendium of Soil Fungi. Vol. 1. Ed., K. H. DOMSH *et al.*, pp. 435~437, Academic Press, 1980
- 2) LINNEMANN, G.: Familie *Mortierellaceae*. In *Mucorales eine Beschreibung aller Gattungen und Arten dieser Pilzgruppe*. Ed., H. ZYCHA *et al.*, pp. 192~194, Verlag von Cramer, J., 1969
- 3) MORITA, T.; H. KATO, S. IWANAGA, K. TAKADA, T. KIMURA & S. SAKAKIBARA: New fluorogenic substrates for α -thrombin, factor Xa, kallikreins, and urokinase. *J. Biochem.* 82: 1495~1498, 1977
- 4) AOYAGI, T.; T. TAKEUCHI, A. MATSUZAKI, K. KAWAMURA, S. KONDO, M. HAMADA, K. MAEDA & H. UMEZAWA: Leupeptins, new protease inhibitors from actinomycetes. *J. Antibiotics* 22: 283~286, 1969
- 5) MAEDA, K.; K. KAWAMURA, S. KONDO, T. AOYAGI, T. TAKEUCHI & H. UMEZAWA: The structure and activity of leupeptins and related analogs. *J. Antibiotics* 24: 402~404, 1971
- 6) MILLOT, C.; J. BRONDEAU & D. CANET: Determination of mutual coupling in ¹H NMR spectra by semiselective excitation. *J. Magn. Reson.* 58: 143~148, 1984
- 7) BAUER, C.; R. FREEMAN, T. FRENKIEL, J. KEELER & A. J. SHAKA: Gaussian pulses. *J. Magn. Reson.* 58:

[†] Configurations of the amino acids were determined by the following HPLC conditions. Leucine: Column YMC-pack FL-ODS3, 4.6 i.d. × 30 mm; mobile phase 2 mM *N,N*-dipropyl-L-alanine, 1 mM copper acetate; flow rate 1.0 ml/minute; detection UV 230 nm. Arginine: Column TSK-GEL Enantio L-1, 4.6 i.d. × 250 mm; mobile phase 1 mM copper sulfate; flow rate 1.0 ml/minute; detection UV 210 nm.

442~457, 1984

- 8) TALLEY, E. A.; T. J. FITZPATRICK & W. L. PORTER:
Formation of fumaramic acid from asparagine in

phosphate buffer. J. Am. Chem. Soc. 81: 174~175,
1959